Involvement of pituitary adenylate cyclase-activating polypeptide II vasoactive intestinal peptide 2 receptor in mouse neocortical astrocytogenesis

Journal of Neurochemistry

Volumn 70, Issue 5, 1998, Pages 2165-2173

  Zupan, Véronique ^a   Hill, Joanna M ^b   Brenneman, Douglas E ^b   Gozes, Illana ^c   Fridkin, Mati ^d   Robberecht, Patrick ^e   Evrard, Philippe ^a   Gressens, Pierre ^a,f  

^a INSERM   (France)

^b EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH AND HUMAN DEVELOPMENT   (United States)

^c TEL AVIV UNIVERSITY   (Israel)

^d WEIZMANN INSTITUTE OF SCIENCE   (Israel)

^e FREE UNIVERSITY OF BRUSSELS   (Belgium)

^f HÔPITAL ROBERT DEBRÉ   (France)

Author keywords

5 Bromo 2' deoxyuridine; Activity dependent neurotrophic factor; Cyclic AMP; Glial fibrillary acidic protein; Growth factor; Ro 25 1553

Indexed keywords

ADENYLATE CYCLASE ACTIVATOR; VASOACTIVE INTESTINAL POLYPEPTIDE RECEPTOR;

ANIMAL TISSUE; ARTICLE; ASTROCYTE; CONTROLLED STUDY; EMBRYO; EMBRYO DEVELOPMENT; HYPOPHYSIS; MOUSE; NEOCORTEX; NERVOUS SYSTEM DEVELOPMENT; NEUROCHEMISTRY; NONHUMAN; PRIORITY JOURNAL;

ANIMALIA; RODENTIA;

EID: 0031969964     PISSN: 00223042     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1471-4159.1998.70052165.x     Document Type: Article

References (49)

1. Angevine J. B. and Sidman R. L. (1961) Autoradiographic study of cell migration during histogenesis of cerebral cortex of the mouse. Nature 192, 766-768.
2. Arimura A. (1992) Receptors for pituitary adenylate cyclase-activating polypeptide. Comparison with vasoactive intestinal peptide receptors. Trends Endocrinol. Metab. 3, 288-294.
3. Arimura A., Somogyvari-Vigh A., Well C., Fiore R. C., Tatsuno I., Bay V., and Brenneman D. E. (1994) PACAP functions as a neurotrophic factor. Ann. NY Acad. Sci. 739, 228-243.
4. Brenneman D. E. and Eiden L. E. (1986) Vasoactive intestinal peptide and electrical activity influence neuronal survival. Proc. Natl. Acad. Sci. USA 83, 1159-1162.
5. Brenneman D. E. and Oozes I. (1996) A femtomolar-acting neuroprotective peptide. J. Clin. Invest. 97, 2296-2307.
6. Brenneman D. E., Eiden L. E., and Siegel R. E. (1985) Neurotrophic action of VIP on spinal cord cultures. Peptides 6(Suppl.), 35-39.
7. Brenneman D. E., Nicol T., Warren D., and Bowers L. M. (1990) Vasoactive intestinal peptide: a neurotrophic releasing agent and an astroglial mitogen. J. Neurosci. Res. 25, 386-394.
8. Brenneman D. E., Hill J. M., Glazner G. W., Gozes I., and Phillips T. M. (1995) Interleukin-1 alpha and vasoactive intestinal peptide: enigmatic regulation of neuronal survival. Int. J. Dev. Neurosci. 13, 187-200.
9. Delanay C. L., Brenner M., and Messing A. (1996) Conditional ablation of astrocytes in postnatal transgenic mice. J. Neurosci. 16, 6908-6918.
10. Fatatis A., Holtzclaw L. A., Avidor R., Brenneman D. E., and Russel J. T. (1994) Vasoactive intestinal peptide increases intracellular calcium in astroglia: synergism with alpha-adrenergic receptors. Proc. Natl. Acad. Sci. USA 91, 2036-2040.
11. Festoff B. E., Nelson P. G., and Brenneman D. E. (1996) Prevention of activity-dependent neuronal death: vasoactive intestinal poly-peptide stimulates astrocytes to secrete the thrombin-inhibiting, neurotrophic serpin, protease nexin. J. Neurobiol. 30, 255-266.
12. Gourlet P., Vandermeers A., Vandermeers-Piret M. C., Rathé J., De Neef P., and Robberecht P. (1995) Fragments of pituitary adenylate cyclase activating polypeptide discriminate between type I and II recombinant receptors. Eur. J. Pharmacol. 287, 7-11.
13. Gourlet P., Vertongen P., Vandermeers A., Vandermeers-Piret M. C., Rathe J., de Neef P., Waelbroek M., and Robberecht P. (1997) The long-acting vasoactive intestinal peptide agonist Ro 25-1553 is highly selective of the VIP2 receptor subclass. Peptides 18, 403-408.
14. Gozes I. and Brenneman D. E. (1989) VIP: molecular biology and neurobiological functions. Mol. Neurobiol. 3, 201-236.
15. Gozes I., Meltzer E., Rubinraut S., and Brenneman D. E. (1989) Vasoactive intestinal peptide potentiates sexual behavior: inhibition by a novel antagonist. Endocrinology 125, 2945-2949.
16. Gozes I., McCune S. K., Jacobson L., Warren D., Moody T. W., Fridkin M., and Brenneman D. E. (1991a) An antagonist to vasoactive intestinal peptide affects cellular functions in the central nervous system. J. Pharmacol Exp. Ther. 257, 959-966.
17. Gozes Y., Brenneman D. E., Fridkin M., Asofsky R., and Gozes I. (1991b)A VIP antagonist distinguishes VIP receptors in spinal cord and lymphocytes. Brain Res. 540, 319-321.
18. Gozes I., Reshef A., Salah D., Rubinraut S., and Fridkin M. (1994) Stearyl-norleucine-VIP: a novel VIP analog for non invasive impotence treatment. Endocrinology 134, 2121-2125.
19. Gozes I., Lilling G., Glazer R., Ticher A., Ashkenazi I. E., Davidson A., Rubinraut S., Fridkin M., and Brenneman D. E. (1995) Superactive lipophilic peptides discriminate multiple vasoactive intesti-nal peptide receptors. J. Pharmacol. Exp. Ther. 273, 161-167.
20. Gozes I., Bardea A., Reshef A., Zamostiano R., Zhukovsky S., Rubinraut S., Fridkin M., and Brenneman D. E. (1996) Neuroprotective strategy for Alzheimer disease: intranasal administration of a fatty neuropeptide. Proc. Nail. Acad. Sci. USA 93, 427-432.
21. Gressens P., Richelme C., Khadim H. J., Gadisseux J. F., and Evrard P. (1992a) The germinative zone produces the most cortical astrocytes after neuronal migration in the developing mammalian brain. Biol. Neonate 61, 4-24.
22. Gressens P., Kosofsky B. E., and Evrard P. (1992b) Cocaine-induced disturbances of neurogenesis in the developing murine brain. Neurosci. Lett. 140, 113-116.
23. Gressens P., Lammens M., Picard J. J., and Evrard P. (1992c) Ethanol-induced disturbances of gliogenesis and neurogenesis in the developing murine brain. An in vitro and in vivo immunohistochemical, morphological, and ultrastructural study. Alcohol Alcohol. 27, 219-226.
24. Gressens P., Hill J. M., Gozes I., Fridkin M., and Brenneman D. E. (1993) Growth factor function of vasoactive intestinal peptide in whole cultured mouse embryos. Nature 362, 155-158.
25. Gressens P., Hill J. M., Paindaveine B., Gozes I., Fridkin M., and Brenneman D.E. (1994) Severe microcephaly induced by blockade of vasoactive intestinal peptide function in the primitive neuroepithelium of the mouse. J. Clin. Invest. 94, 2020-2027.
26. Gressens P., Marret S., Hill J. M., Brenneman D. E., Gozes I., Fridkin M., and Evrard P. (1997a) Vasoactive intestinal peptide prevents excitotoxic cell death in the murine developing brain. J. Clin. Invest. 100, 390-397.
27. Gressens P., Muaku S., Besse L., Nsegbe E., Gallego J., Delpech B., Gaultier C., Evrard P., Ketelslegers P., and Maker D. (1997b) Maternal protein restriction early in rat pregnancy alters brain development in the progeny. Dev. Brain Res. 103, 21-35.
28. Hill J. M., Gozes I., Hill J. L., Fridkin M., and Brenneman D. E. (1991) Vasoactive intestinal peptide antagonist retards the development of neonatal behaviors in the rat. Peptides 12, 187-192.
29. Hill J. M., Harris A., and Hilton-Clarke D. I. (1992) Regional distribution of guanine nucleotide-sensitive and guanine nucleotide-insensitive vasoactive intestinal peptide receptors in rat brain. Neuroscience 48, 925-932.
30. Hill J. M., Agoston D. V., Gressens P., and McCune S. K. (1994a) Distribution of VIP mRNA and two distinct VIP binding sites in the developing rat brain: relation to ontogenic events. J. Comp. Neurol. 342, 186-205.
31. Hill J. M., Mervis R. F., Politi J., McCune S. K., Gozes I., Fridkin M., and Brenneman D. E. (1994b) Blockade of VIP during neonatal development induces neuronal damages and increases VIP and VIP receptors in brain. Ann. NY Acad. Sci. 739, 211-225.
32. Hill J. M., McCune S. K., Alvero R. J., Glazner G. W., Henins K. A., Stanziale S. F., Keimowitz J. R., and Brenneman D. E. (1996) Maternal vasoactive intestinal peptide and the regulation of embryonic growth in rodents. J. Clin. Invest. 97, 202-208.
33. Inagaki N., Yoshida H., Mizuta M., Mizuno N., Fujii Y., Gonoi T., Miyazaki J. I., and Seino S. (1994) Cloning and functional characterization of a third pituitary adenylate cyclase-activating polypeptide receptor subtype expressed in insulin-secreting cells. Proc. Natl. Acad. Sci. USA 91, 2679-2683.
34. Ishiara T., Shigemoto R., Mori K., Takahashi K., and Nagata S. (1992) Functional expression and tissue distribution of a novel receptor for vasoactive intestinal peptide. Neuron 8, 811-819.
35. Jammes J. L. and Gilles F. H. (1983) Telencephalic development: matrix volume and isocortex and allocortex surface areas, in The Developing Human Brain - Growth and Epidemiologic Neuropathology (Gilles F. H., Leviton A., and Dooling E. C., eds), pp. 87-93. Wright PSG, Boston.
36. Kimelberg H. and Norenberg M. (1989) Astrocytes. Sci. Am. 260, 44-52.
37. Krueger B. K., Burne J. F., and Raff M. C. (1995) Evidence for large-scale astrocyte death in the developing cerebellum. J. Neurosci. 15, 3366-3374.
38. Loughlin S. E. and Fallon J. H. (1993) Neurotrophic Factors. Academic Press, San Diego.
39. 2 receptor: molecular characterization of a cDNA encoding a novel receptor for vasoactive intestinal peptide. FEBS Lett. 334, 3-8.
40. Magistretti P. J. and Schorderet M. (1984) VIP and noradrenaline act synergistically to increase cyclic AMP in cerebral cortex. Nature 308, 280-282.
41. O'Donnell M., Garippa R. J., Rinaldi N., Selig W. M., Simko B., Renzetti L., Tannu S. A., Wasserman M. A., Welton A., and Bolin D. R. (1994) Ro 25-1553: a novel long-acting vasoactive intestinal peptide agonist. Part I: In vitro bronchodilatator studies. J. Pharmacol. Exp. Ther. 270, 1282-1288.
42. Olah Z., Lehel C., Anderson W. B., Brenneman D. E., and Agoston D. V. (1994) Subnanomolar concentration of VIP induces the nuclear translocation of protein kinase C in neonatal rat cortical astrocytes. J. Neurosci. Res. 39, 355-363.
43. Ottesen B., Ulrichsen H., Fahrenkrug J., Larsen J. J., Wagner G., Schierup L., and Sondergaard F. (1982) Vasoactive intestinal polypeptide and the female genital tract: relationship to reproductive phase and delivery. Am. J. Obstet. Gynecol. 143, 414-420.
44. Pincus D. W., DiCicco-Bloom E. M., and Black I. B. (1990) Vasoactive intestinal peptide regulates mitosis, differentiation and survival of cultured sympathetic neuroblasts. Nature 343, 564-567.
45. Pisegna J. R. and Wank S. A. (1993) Molecular cloning and functional expression of the pituitary adenylate cyclase-activating polypeptide type I receptor. Proc. Natl. Acad. Sci. USA 90, 6345-6349.
46. Spengler D., Waeber C., Pantaloni C., Hoelboer F., Bockaert J., Seeburg P. H., and Journot L. (1993) Differential signal transduction by five splice variants of the PACAP receptor. Nature 365, 170-175.
47. Sreedharan S. P., Patel D. R., Huang J. X., and Goetzl E. J. (1993) Cloning and functional expression of a human neuroendocrine vasoactive intestinal peptide receptor. Biochem. Biophys. Res. Commun. 193, 546-553.
48. Tatsuno I., Somogyvari-Vigh A., and Arimura A. (1994) Developmental changes of pituitary adenylate cyclase activating polypeptide (PACAP) and its receptor in the rat brain. Peptides 15, 55-60.
49. Waschek J. A., Ellison J., Bravo D. T., and Handley V. (1996) Embryonic expression of vasoactive intestinal peptide (VIP) and VIP receptor genes. J. Neurochem. 66, 1762-1765.